Zontivity is owned by Xspire Pharma.
Zontivity contains Vorapaxar Sulfate.
Zontivity has a total of 2 drug patents out of which 0 drug patents have expired.
Zontivity was authorised for market use on 08 May, 2014.
Zontivity is available in tablet;oral dosage forms.
Zontivity can be used as reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad), reduction of thrombotic cardiovascular events.
The generics of Zontivity are possible to be released after 23 December, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7713999||XSPIRE PHARMA||Thrombin receptor antagonists|| |
(1 year, 2 months from now)
|US7304078||XSPIRE PHARMA||Thrombin receptor antagonists|| |
(4 years from now)
Drugs and Companies using VORAPAXAR SULFATE ingredient
Market Authorisation Date: 08 May, 2014
Treatment: Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad); Reduction of thrombotic cardiovascular events
Korea, Republic of
Taiwan, Province of China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic